American Professional Society of ADHD and Related Disorders

APSARD nears publishing adult ADHD guidelines. Here's what resources you can expect to see upon their publication.

New US adult ADHD guidance nears publication, promising clearer diagnosis, comorbidity screening, and clinician training to curb misdiagnosis.

APSARD's US Adult ADHD Guidelines have advanced to Stage 3, the last review phase before a targeted fall 2026 publication.

FDA clears first triple reuptake ADHD drug Simtriyo, offering nonstimulant relief for adults and kids 6+ with executive and emotional symptoms.

Learn how objective digital tests sharpen adult ADHD diagnosis and guide treatment.

APSARD 2026 highlights: stimulant safety vs substance use, ADHD in pregnancy, and new nonstimulants.

Discover insights from Lauren Kenworthy, PhD on treating comorbid ADHD and autism.

Douglas Leffa, MD, PhD, shares highlights from a poster at the APSARD conference examining severity and age of diagnosis.

Gerald Maguire, MD, discusses the unmet needs of patients with comorbid ADHD and stuttering.

Tim Wilens, MD, discussed mechanism of action and efficacy of new medications at APSARD Conference.

From APSARD 2026, a patient journey demonstrates opportunities in psychiatric education on stuttering and emerging treatment approaches.

Timothy Wilens, MD, shares highlights and clinical implications for ADHD from the APSARD Annual Conference.

Review the misperceptions patients and clinicians may have about ADHD diagnosis and treatment.

Experts discuss the complex relationship between ADHD treatment and substance use disorder.

Barry Herman, MD, shares insights on real-world data of online ADHD assessment tool and telepsychiatry.

Allison Baker, MD, shared insights on supporting women before, during, and after pregnancy at the APSARD conference.

Explore key insights on ADHD treatment barriers and the long-term outcomes for adolescents diagnosed with the disorder.

Benjamin E. Yerys, PhD, shares clinical insights on the impact of the comorbidity at the APSARD Conference.

Poster discusses evidence-based strategies for managing adult ADHD, including medication guidelines and considerations for comorbid conditions.

Poster presented at the APSARD Annual Conference demonstrates the importance of genetic testing in ADHD.

Showcasing cutting edge research and exploring best practices in ADHD diagnosis and treatment.

Explore the most recent data on adult ADHD with the president of the American Professional Society for ADHD and Related Disorders.

Check out these APSARD 2024 updates from Greg Mattingly, MD, president of the American Professional Society for ADHD and Related Disorders.

The results were shared in a poster presentation at the 2024 APSARD Annual Meeting.

APSARD tackles the first US adult ADHD treatment guidelines.

In an exclusive interview, APSARD President Elect Greg Mattingly, MD, tells Psychiatric Times readers what they can expect at this year's meeting.